Drug Rivals Work Together to Battle Melanoma


June 23, 2010

CNBC.com blog

A CNBC.com guest column by Lynn Schuchter, MD, chief of Hematology/Oncology, notes that conducting studies of promising melanoma drugs in combination is challenging, because very few drugs have been approved for melanoma. Combination therapy involves putting together drugs that are still in clinical trials, including those held by different companies. To help overcome these challenges, the Melanoma Research Foundation (MRF) has recently formed collaboration among top melanoma experts (clinicians and scientists), which will look to partner with pharmaceutical companies and government to pool knowledge, resources and efforts to generate new breakthroughs in treatment. MRF's Breakthrough Consortium is committed to accelerate the discovery of effective melanoma treatments through coordinated development of new combinations... read more